Australia - English - Department of Health (Therapeutic Goods Administration)

bppr consulting - sodium bicarbonate -

Australia - English - Department of Health (Therapeutic Goods Administration)

bppr consulting - naloxone hydrochloride dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

bppr consulting - calcium chloride dihydrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - certolizumab pegol 200mg - solution for injection - 200 mg - active: certolizumab pegol 200mg excipient: sodium acetate sodium chloride water for injection - cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients. · combined with mtx in case of either an inadequate response or intolerance to previous therapy with one or more disease-modifying antirheumatic drugs (dmards) or · as monotherapy in case of a contraindication or intolerance to mtx

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ucb pharma sa-nv - piracetam 1200 mg - film-coated tablet - 1200 mg - piracetam 1200 mg - piracetam

Ireland - English - HPRA (Health Products Regulatory Authority)

ucb (pharma) ireland limited - cetirizine dihydrochloride - film-coated tablet - 10 milligram(s) - piperazine derivatives; cetirizine - piperazine derivatives - in adults and paediatric patients 6 years and above: cetirizine is indicated for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis. cetirizine is indicated for the relief of symptoms of chronic idiopathic urticaria.

Israel - English - Ministry of Health

neopharm ltd, israel - brivaracetam - solution (oral) - brivaracetam 10 mg / 1 ml - brivaracetam - briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Israel - English - Ministry of Health

neopharm ltd, israel - certolizumab pegol - solution for injection - certolizumab pegol 200 mg/ml - certolizumab pegol - rheumatoid arthritis:cimzia, in combination with methotrexate (mtx), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate, has been inadequate. cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.axial spondyloarthritis:cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising: ankylosing spondylitis (as): adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). axial spondyloarthritis without radiographic evidence of as adults with severe active axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated c reactive protein (crp) and /or magnetic resonance imaging (mri), who have had an inadequate response to, or are intolerant to nsaids. crohn's disease :cimzia is indicated for reducing signs and symptoms of crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.plaque psoriasis:cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who arecandidates for systemic therapy.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - bifenthrin; n-methyl-2-pyrrolidone; liquid hydrocarbon - emulsifiable concentrate - bifenthrin pyrethroid active 400.0 g/l; n-methyl-2-pyrrolidone solvent other 100.0 g/l; liquid hydrocarbon solvent other 426.0 g/l - insecticide - commercial building/structure - external | domestic building/structure - external a | foundation or vertical barrier | framing t - ant | cockroach | european house borer | flea | fly | furniture beetle | mosquito | paper nest wasp | powderpost beetle | spider | subterranean termite | termite | termite - excluding m. darwiniensis | tick - except paralysis tick | timber beetle | adult mosquitoes | argentine ant | ctenocephalides spp. | drywood termite | ground fleas | large cockroach | papernest wasps | pharaoh ant | small cockroach | subterranean termite

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - colchicine - oral tablet - 500microgram